The peroxisome proliferator-activated receptor α activator, Wy14,643, is anti-inflammatory in vivo

Inflammopharmacology

Volumn 12, Issue 5-6, 2005, Pages 493-504

  Colville Nash, Paul ^a,b   Willis, Dean ^a   Papworth, Jonathan ^a   Freemantle, Claire ^a   Lam, Connie ^a   Andrews, Gemma ^a   Willoughby, Derek ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ST HELIER HOSPITAL   (United Kingdom)

Author keywords

Eicosanoids; Inflammation; Leukotrienes; Peroxisome proliferator activated receptors; Prostaglandins

Indexed keywords

3 [3 TERT BUTYLTHIO 1 (4 CHLOROBENZYL) 5 ISOPROPYL 2 INDOLYL] 2,2 DIMETHYLPROPIONIC ACID; ARACHIDONIC ACID; INDOMETACIN; LEUKOTRIENE B4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIRINIXIC ACID; PROSTAGLANDIN E2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DEGRADATION; DOSE RESPONSE; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; INFLAMMATION; MOUSE; NEUTROPHIL; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OTITIS; PEROXISOME; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; REFERENCE VALUE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONATE 5-LIPOXYGENASE; DINOPROSTONE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EAR, EXTERNAL; EDEMA; FEMALE; INDOLES; INDOMETHACIN; INFLAMMATION; LEUKOTRIENE B4; LIPOXYGENASE INHIBITORS; MICE; NEUTROPHILS; PALMITOYL COENZYME A; PEROXISOMES; PPAR ALPHA; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; PYRIMIDINES;

EID: 27744557391     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856005774382724     Document Type: Article

References (18)

1. Adams, J. L., Garigipati, R. S., Sorenson, M., Schmidt, S. J., Brian, W. R., Newton, J. F., Tyrrell, K. A., Garver, E., Yodis, L. A., Chabot-Fletcher, M., Tzimas, M., Webb, E. F., Breton, J. J. and Griswold, D. E. (1996). Bicyclic N-hydroxyurea inhibitors of 5-lipoxygenase: pharmacodynamic, pharmacokinetic, and in vitro metabolic studies characterising N-hydroxy-N-(2,3-dihydro-6- (phenylmethoxy)-3-benzofuranyl)urea, J. Med. Chem. 36, 5035-5046.
2. Chen, X.-Y., Sheller, J. R., Johnson, E. N. and Funk, C. D. (1994). Role of leukotrienes revealed by targetted disruption of the 5-lipoxygenase gene, Nature 372, 179-182.
3. Colville-Nash, P. R., Qureshi, S. S., Willis, D. and Willoughby, D. A. (1998). Inhibition of inducible nitric oxide synthase by peroxisome proliferator-activated receptor agonists: correlation with induction of heme oxygenase 1, J. Immunol. 161, 978-984.
4. Devchand, P. R., Keller, H., Peters, J. M., Vazquez, M., Gonzalez, F. J. and Wahli, W. (1996). The PPARalpha-leukotriene B4 pathway to inflammation control, Nature 384, 39-43.
5. 2α in Zellweger syndrome, J. Clin. Invest. 88, 978-984.
6. Dreyer, C., Krey, G., Keller, H., Givel, F., Helftenbein, G. and Wahli, W. (1992). Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors, Cell 68, 879-887.
7. Gad, S. C., Dunn, B. J., Dobbs, D. W., Reilly, C. and Walsh, R. D. (1986). Development and validation of an alternative dermal sensitisation test: the murine ear swelling test (MEST), Toxicol. Appl. Pharmacol. 84, 93-114.
8. Jiang, C., Ting, A. T. and Seed, B. (1998). PPAR-γ agonists inhibit production of monocyte inflammatory cytokines, Nature 391, 82-86.
9. Grimes, D., Sturm, R. J., Marinari, L. R., Carlson, R. P., Berkemkopf, J. W., Musser, J. H., Kreft, A. F. and Wiechman, B. M. (1993). Wy-50,295, tromethamine, a novel, orally active 5-lipoxygenase inhibitor: biochemical characterisation and anti-allergic activity, Eur. J. Pharmacol. 236, 217-228.
10. Kliewer, S. A., Forman, B. M., Blumberg, B., Ong, E. S., Borgmeyer, U., Mangelsdorf, D. J., Umesono, K. and Evans, R. M. (1994). Differential expression and activation of a family of murine peroxisome proliferator-activated receptors, Proc. Natl. Acad. Sci. USA 91, 7355-7359.
11. Kota, B. P., Huang, T. H. and Roufogalis, B. D. (2005). An overview on biological mechanisms of PPARs, Pharmacol. Res. 51, 85-94.
12. Lazarow, P. B. (1981). Assay of peroxisomal β-oxidation of fatty acids. Methods Enzymol. 72, 315-319.
13. Ledwith, B. J., Pauley, C. J., Wagner, L. K., Rokos, C. L., Alberts, D. W. and Manam, S. (1997). Induction of cyclooxygenase-2 expression by peroxisome proliferators and non-tetradecanoylphorbol 12,13-myristate-type tumor promoters in immortalized mouse liver cells, J. Biol. Chem. 272, 3707-3714.
14. Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J. and Glass, C. K. (1998). The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation, Nature 391, 79-82.
15. Schoonjans, K., Staels, B. and Auwerx, J. (1996). The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation, Biochim. Biophys. Acta 1302, 93-109.
16. Sheu, M. Y., Fowler, A. J., Kao, J., Schmuth, M., Schoonjans, K., Auwerx, J., Fluhr, J. W., Man, M.-Q., Elias, P. M. and Feingold, K. R. (2002). Topical peroxisome proliferator activated receptor-α activators reduce inflammation in irritant and allergic contact dermatitis models, J. Invest. Dernatol. 118, 94-101.
17. Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nature 231, 232-235.
18. Warner, T. D., Giuliano, F., Vojnovic, I., Bukasa, A., Mitchell, J. A. and Vane, J. R. (1999). Non-steroid drug selectivities for cyclo-oxygenase 1 rather than cyclo-oxygenase 2 are associated with human gastrointestinal toxicity: a full in vitro analysis, Proc. Natl Acad. Sci. USA 96, 7563-7568.